XML 55 R47.htm IDEA: XBRL DOCUMENT v3.23.4
Acquisitions - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended
Apr. 18, 2022
Apr. 30, 2022
Mar. 31, 2018
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Acquisitions                  
Goodwill           $ 1,452,338      
Contingent consideration, current portion         $ 593,037        
Pelican Therapeutics, Inc.                  
Acquisitions                  
Ownership interest in subsidiary       85.00% 85.00%   85.00% 80.00%  
Pelican Therapeutics, Inc.                  
Acquisitions                  
Percentage of voting interests acquired in acquisition                 80.00%
Cash consideration     $ 200,000            
Milestone payment       $ 0          
Pelican Therapeutics, Inc. | Stockholders                  
Acquisitions                  
Cash consideration     $ 300,000            
Elusys Therapeutics                  
Acquisitions                  
Earn out payments period 12 years                
Percentage of earn out payments 10.00%                
Frequency of periodic earn out payment 1 year                
Period of occurrence of earn payment 9 years                
Receivable consideration $ 22,318,685                
Consideration paid   $ 20,800,000              
Holding back related to future fulfillment cost   $ 1,500,000              
Contract receivables 24,526,232                
Fair value of the purchase consideration 42,900,000                
Cash consideration 3,000,000                
Deferred cash consideration 2,000,000                
Fair value of contingent and deferred consideration liabilities $ 37,900,000                
Discount rate for deferred consideration 24.00%                
Discount rate for earn out liabilities 14.00%                
Preliminary value of Additional Earn Out liability as percentage 80.00%                
Goodwill $ 3,301,960                
Goodwill deductible for tax purposes 15 years